WallStreetZenWallStreetZen

NASDAQ: LYEL
Lyell Immunopharma Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

LYEL past revenue growth

How has LYEL's revenue growth performed historically?
Company
-99.85%
Industry
148.4%
Market
16.96%
LYEL's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
LYEL's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

LYEL earnings and revenue history

Current Revenue
$130.0k
Current Earnings
-$234.6M
Current Profit Margin
-180,486.2%

LYEL Return on Equity

Current Company
-32.7%
Current Industry
-63.5%
Current Market
188%
LYEL's Return on Equity (-32.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when LYEL announces earnings.

LYEL Return on Assets

Current Company
-28.8%
Current Industry
2.9%
LYEL is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

LYEL Return on Capital Employed

Current Company
-32.79%
Current Industry
19.5%
LYEL's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

LYEL vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
LYEL$130.00k-$214.38M-$234.63M-33.30%N/A
SVRA$0.00-$50.09M-$54.70M-100.00%N/A
NUVB$0.00-$75.65M-$75.80MN/AN/A
NVAX$983.71M-$487.39M-$545.06M+95.68%N/A
AVTE$0.00-$75.37M-$75.52MN/AN/A
View Top Biotech Stocks

LYEL earnings dates

Next earnings date
May 7, 2024

Lyell Immunopharma Earnings & Revenue FAQ

What were LYEL's earnings last quarter?

On Invalid Date, Lyell Immunopharma (NASDAQ: LYEL) reported Q4 2023 earnings per share (EPS) of -$0.20, up 566.67% year over year. Total Lyell Immunopharma earnings for the quarter were -$52.93 million. In the same quarter last year, Lyell Immunopharma's earnings per share (EPS) was -$0.03.

If you're new to stock investing, here's how to buy Lyell Immunopharma stock.

What was LYEL's earnings growth in the past year?

As of Q2 2024, Lyell Immunopharma's earnings has grown year over year. Lyell Immunopharma's earnings in the past year totalled -$234.63 million.

What is LYEL's earnings date?

Lyell Immunopharma's earnings date is Invalid Date. Add LYEL to your watchlist to be reminded of LYEL's next earnings announcement.

What was LYEL's revenue last quarter?

On Invalid Date, Lyell Immunopharma (NASDAQ: LYEL) reported Q4 2023 revenue of $13.00 thousand up 99.97% year over year. In the same quarter last year, Lyell Immunopharma's revenue was $48.39 million.

What was LYEL's revenue growth in the past year?

As of Q2 2024, Lyell Immunopharma's revenue has grown -99.85% year over year. This is 248.25 percentage points lower than the US Biotechnology industry revenue growth rate of 148.4%. Lyell Immunopharma's revenue in the past year totalled $130.00 thousand.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.